Telomerase activity in colorectal cancer and its relationship to bcl-2 expression

Journal of Surgical Oncology

Volumn 73, Issue 4, 2000, Pages 219-223

  Iida, Atsushi ^a   Yamaguchi, Akio ^a   Hirose, Kazuo ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

bcl 2; Carcinoma; p53; Telomerase

Indexed keywords

PROTEIN BCL 2; TELOMERASE;

ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADENOCARCINOMA; APOPTOSIS; COLONIC NEOPLASMS; COLORING AGENTS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECTAL NEOPLASMS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034050656     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(200004)73:4<219::AID-JSO6>3.0.CO;2-Q     Document Type: Article

References (29)

1. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 1993;341: 1251-1254.
2. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
3. Korsmeyer SJ: Regulators of cell death. Trends Genet 1995;11: 101-105.
4. Vaux DL, Cory S, Adams JM: bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1998;335:440-442.
5. Korsmeyer S: bcl-2 initiates a new category of oncogenes: Regulator of cell death. Blood 1992;80:879-886.
6. Alnemri ES, Fernandes TF, Haldar S, et al.: Involvement of bcl-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer Res 1992;52:491-495.
7. Wang Y, Szekely L, Okan I, et al.: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993;8:3427-3431.
8. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell Growth Differ 1993;4:41-47.
9. Fisher TC, Milner AE, Gregory CD, et al.: Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993;5 3:3321-3326.
10. Allsopp TE, Wyatt S, Paterson HF, et al.: Protooncogene bcl-2 can selectively rescue neurotropic factor dependent neurons from apoptosis. Cell 1993;73:295-307.
11. Harley CB: Telomere loss: Mitotic clock or genetic bomb? Mutat Res 1991;256:271-282.
12. Shay JW, Werbin H, Wright WE: Telomere shortening may contribute to aging and cancer: A perspective. Mol Cell Differ 1994; 2:1-21.
13. Blackburn EH: Structure and function of telomeres. Nature 1991; 350:569-573.
14. Wright WE, Shay JW: Time, telomeres and tumors: Is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995;5:293-297.
15. Shay JW, Wright WE: Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.
16. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
17. Hiyama K, Hiyama E, Ishioka S, et al.: Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895-902.
18. Counter CM, Hirte HW, Bacchetti S, et al.: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994:91: 2900-2904.
19. Tahara H, Nakanishi T, Kitamoto M, et al.: Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995;55:2734-2736.
20. Sommerfeld HJ, Meeker AK, Piatyszek MA, et al.: Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-222.
21. Chadeneau C, Hay K, Hirte HW, et al.: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1955;55:2533-2536.
22. Langford LA, Piatyszek MA, Xu R, et al.: Telomerase activity in human brain tumors. Lancet 1995;346:1267-1268.
23. Ohyashiki JH, Ohyashiki K: A nonradioactive, fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. Trends Genet 1996;12:395-396.
24. Hiyama E, Yokoyama T, Tatsumoto N, et al.: Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-3262.
25. Valassiadou KE, Sefanaki K, Tzardi M, et al.: Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 1997;17:2517-2526.
26. Mueller J, Mueller E, Hoepner I, et al.: Expression of bcl-2 and p53 in de novo and ex-adenoma colon carcinoma: A comparative immunohistochemical study. J Pathol 1996;180:259-265.
27. Flohil CC, Janssen PA, Bosman FT: Expression of bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol 1996;178:393-397.
28. Bosari S, Moneghini L, Graziani D, et al.: bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995;26:534-540.
29. Yamaguchi A, Nakagawara G, Kurosawa Y, et al.: p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its relationship to prognostic significance. Br J Cancer 1993;68: 399-402.